CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Upstream Bio, Inc. (UPB) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Upstream Bio, Inc. (UPB)

Pharmaceutical Preparations · market cap $285M · as of 2026-10-27

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-01 (est.)
Conference
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Upstream Bio (UPB) is a ~$151M market-cap, 52-employee biotech whose pipeline in our data is a single asset, verekitug, in Phase 2 for severe asthma and for chronic rhinosinusitis with nasal polyps (CRSwNP). Cash is $79.4M with a stated 22-month runway, so the company is funded through the estimated Phase 2 readouts in Sept/Oct 2027. At ~$2.75 the enterprise value is roughly $72M (market cap less cash).
The catalyst path
  • 2026-12-01 (est.)Conferenceimp 2/10
  • 2027-09-15 (est.)Phase 2 · Verekitugimp 7/10
  • 2027-10-15 (est.)Phase 2 · Verekitugimp 7/10
Pipeline
AssetPhaseIndication
Verekitug (UPB-101)Phase 2Chronic Rhinosinusitis With Nasal Polyps
VerekitugPhase 2Severe Asthma
Price & technical context
3-month
-62.6%
6-month
-69.9%
12-month
-89.0%
52-wk range
$2.56–$32.60
vs 50-day MA
-38.6%
vs 200-day MA
-66.9%
Realized vol
105.2%
Max drawdown
-92.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for UPB (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.